Latest Headlines

  1. Labcorp Launches MyLabcorp™, A New AI-Powered Mobile App Designed To Help Consumers Understand Lab Results And Track Health Trends Over Time 5/20/2026

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp™, an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience.

  2. Umbrella Lab Announces Documentation And Traceability Update For Dihexa Peptide 5/19/2026

    Umbrella Labs today issued a company announcement confirming an internal documentation and traceability update for dihexa peptide reference material, provided strictly for laboratory developmental research use only.

  3. Helio Genomics Announces Strategic Commercial Partnership With Syneos Health® To Accelerate Nationwide Adoption Of HelioLiver™, A Breakthrough AI-Powered Blood Test For Early Liver Cancer Detection 5/19/2026

    Helio Genomics, a leading AI-powered TechBio company focused on revolutionizing early cancer detection, today announced a strategic commercial partnership with Syneos Health®, a leading fully integrated biopharmaceutical solutions organization.

  4. Bracco And ACIST Medical Systems Announce U.S. FDA Clearance Of ACIST Pro™ Diagnostic System 5/18/2026

    ACIST Medical Systems, Inc., a Bracco company and a global leader in advanced contrast management technologies, today announced U.S. Food and Drug Administration (FDA) clearance and U.S. launch of the ACIST Pro™ Diagnostic System, a next-generation variable-rate contrast management solution designed to advance precision, safety and efficiency in image-guided cardiovascular procedures.

  5. Roche Highlights Robust Performance Of Ellis Bio SuperMethyl™ Kits In New Tech Spotlight Evaluating Five Low Input cfDNA Methyl Seq Workflows 5/18/2026

    Ellis Bio today announced that an independent evaluation by Roche, published in a new Tech Spotlight, found that the company's new ultra-mild SuperMethyl™ Max bisulfite conversion chemistry "matched or outperformed the gold standard" when paired with Roche's KAPA EvoPrep® library preparation for low-input cfDNA and genomic DNA (gDNA).

  6. Entry Level Heat Sealer Improves Plate Sealing Consistency 5/18/2026

    For budget conscious labs the Semi-Automated Sheet Heat Sealer from Azenta Life Sciences is the perfect tool for ensuring reliable microplate sealing that supports consistent results across a wide range of applications.

  7. Thermo Fisher Scientific's PPD Clinical Research Business Expands Bioanalytical Capabilities With New Laboratory In Gothenburg, Sweden 5/18/2026

    Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City.

  8. Valar Labs Receives FDA Breakthrough Device Designation For Vesta Bladder Risk Stratify Dx 5/15/2026

    Valar Labs, an AI precision oncology company developing diagnostics that predict cancer treatment response from routine pathology slides, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Vesta Bladder Risk Stratify Dx. With this designation, Vesta Bladder Risk Stratify Dx becomes the first AI-powered digital pathology prognostic test in bladder cancer to receive FDA Breakthrough status, marking a significant milestone for the field of computational pathology and for patients with bladder cancer.

  9. Watchmaker Genomics Expands Molecular Diagnostics Tools Portfolio With Launch Of Stellar RT-qPCR And qPCR Kits 5/14/2026

    Watchmaker Genomics, an innovator in high-performance tools for molecular diagnostic (MDx) assay developers, today announced the expansion of its MDx tools portfolio with the launch of Stellar RT-qPCR and qPCR Kits.

  10. Charles River Laboratories And MEDIPOST Sign Non-Exclusive MOU To Advance GMP Testing Solutions 5/13/2026

    Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization.